Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)